KR100781014B1 - 코발라민 분석 - Google Patents
코발라민 분석 Download PDFInfo
- Publication number
- KR100781014B1 KR100781014B1 KR1020017003485A KR20017003485A KR100781014B1 KR 100781014 B1 KR100781014 B1 KR 100781014B1 KR 1020017003485 A KR1020017003485 A KR 1020017003485A KR 20017003485 A KR20017003485 A KR 20017003485A KR 100781014 B1 KR100781014 B1 KR 100781014B1
- Authority
- KR
- South Korea
- Prior art keywords
- ligand
- holo
- binding
- cobalamin
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 title claims abstract description 124
- 238000004458 analytical method Methods 0.000 title claims abstract description 28
- 239000003446 ligand Substances 0.000 claims abstract description 186
- 102100040423 Transcobalamin-2 Human genes 0.000 claims abstract description 143
- 230000027455 binding Effects 0.000 claims abstract description 119
- 238000003556 assay Methods 0.000 claims abstract description 46
- 102000011409 Transcobalamins Human genes 0.000 claims abstract description 34
- 108010023603 Transcobalamins Proteins 0.000 claims abstract description 34
- 230000009870 specific binding Effects 0.000 claims abstract description 20
- 210000001124 body fluid Anatomy 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims description 79
- 210000002966 serum Anatomy 0.000 claims description 29
- 238000000926 separation method Methods 0.000 claims description 21
- 239000007787 solid Substances 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 11
- 238000002372 labelling Methods 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 230000009260 cross reactivity Effects 0.000 claims description 9
- 239000007790 solid phase Substances 0.000 claims description 8
- 238000004020 luminiscence type Methods 0.000 claims description 7
- 238000012875 competitive assay Methods 0.000 claims description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000011156 evaluation Methods 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- 108010038807 Oligopeptides Proteins 0.000 claims description 2
- 102000015636 Oligopeptides Human genes 0.000 claims description 2
- 210000004381 amniotic fluid Anatomy 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 238000011067 equilibration Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 230000003100 immobilizing effect Effects 0.000 claims description 2
- 238000002823 phage display Methods 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000004873 anchoring Methods 0.000 claims 2
- 102000006240 membrane receptors Human genes 0.000 claims 1
- 102100040396 Transcobalamin-1 Human genes 0.000 abstract description 5
- 239000002245 particle Substances 0.000 description 32
- 102000005962 receptors Human genes 0.000 description 20
- 108020003175 receptors Proteins 0.000 description 20
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000005259 measurement Methods 0.000 description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 10
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 239000004005 microsphere Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 108090001008 Avidin Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000012491 analyte Substances 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 5
- 235000000639 cyanocobalamin Nutrition 0.000 description 5
- 239000011666 cyanocobalamin Substances 0.000 description 5
- 229960002104 cyanocobalamin Drugs 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 3
- 239000003463 adsorbent Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000006249 magnetic particle Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- -1 sheets Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 2
- 206010060860 Neurological symptom Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010037180 Psychiatric symptoms Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical class N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- OAJLVMGLJZXSGX-NDSREFPTSA-L (2r,3s,4s,5r)-2-(6-aminopurin-9-yl)-5-methanidyloxolane-3,4-diol;cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12 Chemical compound [Co+3].O[C@H]1[C@H](O)[C@@H]([CH2-])O[C@H]1N1C2=NC=NC(N)=C2N=C1.C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O OAJLVMGLJZXSGX-NDSREFPTSA-L 0.000 description 1
- MZFOKIKEPGUZEN-AGCMQPJKSA-N (R)-methylmalonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)[C@@H](C(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MZFOKIKEPGUZEN-AGCMQPJKSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JNGRENQDBKMCCR-UHFFFAOYSA-N 2-(3-amino-6-iminoxanthen-9-yl)benzoic acid;hydrochloride Chemical compound [Cl-].C=12C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C2C=1C1=CC=CC=C1C(O)=O JNGRENQDBKMCCR-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- GUQQBLRVXOUDTN-XOHPMCGNSA-N 3-[dimethyl-[3-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 GUQQBLRVXOUDTN-XOHPMCGNSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108050001427 Avidin/streptavidin Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000891367 Homo sapiens Transcobalamin-1 Proteins 0.000 description 1
- 101000891321 Homo sapiens Transcobalamin-2 Proteins 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 241000801593 Pida Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000000987 azo dye Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005250 beta ray Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000003346 cobalamin group Chemical group 0.000 description 1
- 150000001867 cobalamins Chemical class 0.000 description 1
- 229940010007 cobalamins Drugs 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical group [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- ZIYVHBGGAOATLY-UHFFFAOYSA-N methylmalonic acid Chemical compound OC(=O)C(C)C(O)=O ZIYVHBGGAOATLY-UHFFFAOYSA-N 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 150000003901 oxalic acid esters Chemical class 0.000 description 1
- 150000004893 oxazines Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003248 quinolines Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000002821 scintillation proximity assay Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 229910021487 silica fume Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000004897 thiazines Chemical class 0.000 description 1
- 150000005075 thioxanthenes Chemical class 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Lubrication Of Internal Combustion Engines (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Cable Accessories (AREA)
- Liquid Developers In Electrophotography (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Devices For Conveying Motion By Means Of Endless Flexible Members (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Glass Compositions (AREA)
- Polyamides (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9820473.8A GB9820473D0 (en) | 1998-09-18 | 1998-09-18 | Assay |
| GB9820473.8 | 1998-09-18 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020047014817A Division KR100646305B1 (ko) | 1998-09-18 | 1999-09-20 | 코발라민 분석 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20010079854A KR20010079854A (ko) | 2001-08-22 |
| KR100781014B1 true KR100781014B1 (ko) | 2007-11-29 |
Family
ID=10839158
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020017003485A Expired - Lifetime KR100781014B1 (ko) | 1998-09-18 | 1999-09-20 | 코발라민 분석 |
| KR1020047014817A Expired - Lifetime KR100646305B1 (ko) | 1998-09-18 | 1999-09-20 | 코발라민 분석 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020047014817A Expired - Lifetime KR100646305B1 (ko) | 1998-09-18 | 1999-09-20 | 코발라민 분석 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7279283B1 (enExample) |
| EP (2) | EP1443328B1 (enExample) |
| JP (1) | JP4394285B2 (enExample) |
| KR (2) | KR100781014B1 (enExample) |
| CN (2) | CN1322330C (enExample) |
| AT (2) | ATE363076T1 (enExample) |
| AU (1) | AU761498B2 (enExample) |
| BR (1) | BR9913770A (enExample) |
| CA (1) | CA2344193C (enExample) |
| CY (1) | CY1106688T1 (enExample) |
| CZ (2) | CZ298381B6 (enExample) |
| DE (2) | DE69936154T2 (enExample) |
| DK (1) | DK1443328T3 (enExample) |
| ES (2) | ES2234299T3 (enExample) |
| GB (1) | GB9820473D0 (enExample) |
| HU (1) | HU228077B1 (enExample) |
| MX (1) | MXPA01002591A (enExample) |
| NO (2) | NO327771B1 (enExample) |
| NZ (1) | NZ510766A (enExample) |
| PL (2) | PL201360B1 (enExample) |
| PT (2) | PT1443328E (enExample) |
| WO (1) | WO2000017659A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0016460D0 (en) * | 2000-07-04 | 2000-08-23 | Axis Shield Asa | Assay |
| GB0109925D0 (en) * | 2001-04-23 | 2001-06-13 | Axis Shield Asa | Method |
| KR101449340B1 (ko) | 2012-11-06 | 2014-10-13 | 현대자동차주식회사 | 고내열 흡차음재의 제조방법 |
| CN104198598B (zh) * | 2014-07-15 | 2016-03-16 | 汤臣倍健股份有限公司 | 一种维生素b12的测定方法 |
| CN106841017B (zh) * | 2017-01-22 | 2019-05-07 | 耐斯检测技术服务有限公司 | 一种评价辐照或热处理对钴胺素-蛋白结合体影响的方法 |
| CN106693443A (zh) * | 2017-01-23 | 2017-05-24 | 北京美正生物科技有限公司 | 一种维生素b12适配体亲和柱及其制备方法和用途 |
| WO2021030166A1 (en) * | 2019-08-09 | 2021-02-18 | Siemens Healthcare Diagnostics Inc. | Anti-hog tcn1 monoclonal antibodies and methods of production and use thereof |
| EP4220152A4 (en) * | 2020-12-18 | 2024-12-25 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR MEASURING THE RELATIVE FU RATIO BY DYNAMIC ANALYSIS |
| CN113189252A (zh) * | 2021-04-19 | 2021-07-30 | 中国医学科学院北京协和医院 | 一种总钴胺素和氰钴胺的检测方法及其检测试剂盒和应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5374560A (en) * | 1989-04-03 | 1994-12-20 | The University Of Colorado, Inc. | Method for screening and distinguishing between cobalamin and folic acid deficiency based on assay for cystathionine and 2-methylcitric acid |
| KR950701390A (ko) * | 1992-05-08 | 1995-03-23 | 에이. 찰스 모간 2세 | 비타민 B12/ 트랜스코발라민 II 수용체에 대한 항-수용체 제제(Anti-receptor agents to the vitamin B12/ transcobalamin II receptor) |
| US5457055A (en) * | 1986-11-20 | 1995-10-10 | The University Of Colorado Foundation | Diagnostic method for cobalamin deficiency |
| US6274564B1 (en) * | 1996-09-18 | 2001-08-14 | William J. Sarill | Compositions of cobalamin and related corrinoids, and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4273757A (en) * | 1977-06-02 | 1981-06-16 | Yissum Research Development Company | Determination of transcobalamins |
| US4332785A (en) * | 1980-04-09 | 1982-06-01 | University Patents, Inc. | Immunoassay for measurement of reticulocytes, and immunoreactive reagents for use therein |
| CA1180273A (en) * | 1981-06-22 | 1985-01-02 | Technicon Instruments Corporation | Assay of vitamin b in12 xx |
| US4680273A (en) * | 1985-07-29 | 1987-07-14 | Victor Herbert | Assay for vitamin B12 deficiency |
| DE3900650A1 (de) * | 1989-01-11 | 1990-07-12 | Boehringer Mannheim Gmbh | Vitamin-b12-bestimmung |
| US5506109A (en) | 1989-06-26 | 1996-04-09 | Bayer Corporation | Vitamin B12 assay |
| US5310656A (en) | 1989-06-26 | 1994-05-10 | Tritech Partners | Vitamin B12 assay |
| EP0479929B1 (en) * | 1989-06-26 | 1994-04-13 | Tritech Partners | Vitamin b12 assay |
-
1998
- 1998-09-18 GB GBGB9820473.8A patent/GB9820473D0/en not_active Ceased
-
1999
- 1999-09-20 PT PT04009702T patent/PT1443328E/pt unknown
- 1999-09-20 AU AU61026/99A patent/AU761498B2/en not_active Ceased
- 1999-09-20 WO PCT/GB1999/003127 patent/WO2000017659A1/en not_active Ceased
- 1999-09-20 AT AT04009702T patent/ATE363076T1/de active
- 1999-09-20 PL PL382436A patent/PL201360B1/pl unknown
- 1999-09-20 EP EP04009702A patent/EP1443328B1/en not_active Expired - Lifetime
- 1999-09-20 KR KR1020017003485A patent/KR100781014B1/ko not_active Expired - Lifetime
- 1999-09-20 ES ES99947642T patent/ES2234299T3/es not_active Expired - Lifetime
- 1999-09-20 PT PT99947642T patent/PT1114323E/pt unknown
- 1999-09-20 BR BR9913770-4A patent/BR9913770A/pt not_active IP Right Cessation
- 1999-09-20 KR KR1020047014817A patent/KR100646305B1/ko not_active Expired - Lifetime
- 1999-09-20 DE DE69936154T patent/DE69936154T2/de not_active Expired - Lifetime
- 1999-09-20 CZ CZ20023143A patent/CZ298381B6/cs not_active IP Right Cessation
- 1999-09-20 CN CNB2004100055424A patent/CN1322330C/zh not_active Expired - Fee Related
- 1999-09-20 AT AT99947642T patent/ATE283490T1/de active
- 1999-09-20 DE DE69922225T patent/DE69922225T2/de not_active Expired - Lifetime
- 1999-09-20 CN CNB998110396A patent/CN1148580C/zh not_active Expired - Fee Related
- 1999-09-20 JP JP2000571269A patent/JP4394285B2/ja not_active Expired - Lifetime
- 1999-09-20 DK DK04009702T patent/DK1443328T3/da active
- 1999-09-20 NZ NZ510766A patent/NZ510766A/en not_active IP Right Cessation
- 1999-09-20 PL PL347104A patent/PL198095B1/pl unknown
- 1999-09-20 ES ES04009702T patent/ES2287607T3/es not_active Expired - Lifetime
- 1999-09-20 EP EP99947642A patent/EP1114323B1/en not_active Expired - Lifetime
- 1999-09-20 HU HU0103532A patent/HU228077B1/hu not_active IP Right Cessation
- 1999-09-20 CZ CZ20010975A patent/CZ298310B6/cs not_active IP Right Cessation
- 1999-09-20 MX MXPA01002591A patent/MXPA01002591A/es not_active IP Right Cessation
- 1999-09-20 CA CA002344193A patent/CA2344193C/en not_active Expired - Lifetime
-
2000
- 2000-10-04 US US09/679,043 patent/US7279283B1/en not_active Expired - Lifetime
-
2001
- 2001-03-16 NO NO20011353A patent/NO327771B1/no not_active IP Right Cessation
-
2007
- 2007-07-02 CY CY20071100864T patent/CY1106688T1/el unknown
-
2008
- 2008-08-21 NO NO20083610A patent/NO331074B1/no not_active IP Right Cessation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457055A (en) * | 1986-11-20 | 1995-10-10 | The University Of Colorado Foundation | Diagnostic method for cobalamin deficiency |
| US5374560A (en) * | 1989-04-03 | 1994-12-20 | The University Of Colorado, Inc. | Method for screening and distinguishing between cobalamin and folic acid deficiency based on assay for cystathionine and 2-methylcitric acid |
| KR950701390A (ko) * | 1992-05-08 | 1995-03-23 | 에이. 찰스 모간 2세 | 비타민 B12/ 트랜스코발라민 II 수용체에 대한 항-수용체 제제(Anti-receptor agents to the vitamin B12/ transcobalamin II receptor) |
| US6274564B1 (en) * | 1996-09-18 | 2001-08-14 | William J. Sarill | Compositions of cobalamin and related corrinoids, and uses thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5188939A (en) | Displacement immunoassay utilizing an oligavalent labelled antibody | |
| KR100781014B1 (ko) | 코발라민 분석 | |
| CN110196334A (zh) | 血栓调节蛋白化学发光免疫定量检测试剂盒及其制备方法 | |
| EP3818375A1 (en) | Direct immunoassay measurement of autoantibodies | |
| JP3935437B2 (ja) | トランスコバラミンｉｉ分析方法 | |
| EP1257830B1 (en) | Assay for measuring holo-transcobalamin and folate | |
| US7344849B2 (en) | Assay | |
| AU2003203209B2 (en) | Cobalamin assay | |
| ZA200101937B (en) | Cobalamin assay. | |
| NZ525253A (en) | Cobalamin assay |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20010317 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20040920 |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20040920 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20051117 Patent event code: PE09021S01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20060927 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20071030 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20071123 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20071123 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20101101 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20111028 Start annual number: 5 End annual number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20121031 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20121031 Start annual number: 6 End annual number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20131101 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20131101 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20141107 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20141107 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20151016 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20151016 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20161019 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20161019 Start annual number: 10 End annual number: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20171018 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20171018 Start annual number: 11 End annual number: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20181029 Start annual number: 12 End annual number: 12 |
|
| PC1801 | Expiration of term |